Zydus Lifesciences Limited
ZYDUSLIFE
Rang in Aktien
#1776
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Aktienkurs
$12.00
Marktkapitalisierung
$11.97B
Veränderung (1 Tag)
-2.44%
Veränderung (1 Jahr)
5.68%
Land
IN
Handel Zydus Lifesciences Limited (ZYDUSLIFE)
Kategorie
Healthcare
Umsatz von Zydus Lifesciences Limited (ZYDUSLIFE)
Umsatz im Jun 2026 TTM: $3.16B
Laut den aktuellen Finanzberichten von Zydus Lifesciences Limited beträgt der derzeitige Umsatz des Unternehmens (TTM) $3.16B. Im Jahr 2025 erzielte das Unternehmen einen Umsatz von $2.72B eine Steigerung gegenüber dem Umsatz im Jahr 2024, der $2.34B betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Zydus Lifesciences Limited von 2004 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $3.16B | 16.11% |
| 2025 | $2.72B | 15.92% |
| 2024 | $2.34B | 11.77% |
| 2023 | $2.10B | 5.37% |
| 2022 | $1.99B | 1.17% |
| 2021 | $1.97B | 4.00% |
| 2020 | $1.89B | -0.21% |
| 2019 | $1.90B | 3.69% |
| 2018 | $1.83B | 26.46% |
| 2017 | $1.45B | 1.62% |
| 2016 | $1.42B | 2.63% |
| 2015 | $1.39B | 15.37% |
| 2014 | $1.20B | 3.47% |
| 2013 | $1.16B | 15.71% |
| 2012 | $1.00B | 0.20% |
| 2011 | $1.00B | 22.04% |
| 2010 | $820.89M | 45.59% |
| 2009 | $563.82M | -0.43% |
| 2008 | $566.27M | 37.48% |
| 2007 | $411.90M | 26.93% |
| 2006 | $324.50M | 14.00% |
| 2005 | $284.66M | 3.30% |
| 2004 | $275.56M | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 109.54% |
IN
|
